Researcher | University of Cambridge | United Kingdom
Dr. Hengrui Liu is a distinguished researcher at the University of Cambridge, United Kingdom, whose interdisciplinary work spans molecular biology, oncology, pharmacogenomics, and bioinformatics. With a remarkable Scopus h-index of 31, over 2,300 citations, and 55 publications, Dr. Liu has made substantial contributions to understanding cancer biology and translational medicine. His research integrates computational modeling, systems biology, and experimental oncology, focusing on identifying molecular mechanisms underlying drug resistance, tumor progression, and therapeutic targeting.One of Dr. Liu’s notable contributions includes the use of CRISPR screening and cell line IC50 data to uncover genes responsible for trametinib resistance, highlighting potential pathways for targeted cancer therapy. He also explores the role of transcription factors in protein autoubiquitination across multiple cancer types through pan-cancer in-silico profiling, advancing precision oncology approaches. His expertise extends to traditional medicine and integrative therapies, as seen in his recent studies on the role of traditional Chinese medicine (TCM) in improving liver transplantation outcomes, bridging conventional and modern biomedical practices.Dr. Liu’s recent review on the multidimensional role of laminin γ2 (LAMC2) in cancer progression provides a comprehensive understanding of how extracellular matrix components influence tumor behavior and metastasis. His interdisciplinary research brings together molecular mechanisms, clinical relevance, and computational insight, reflecting a holistic approach to biomedical innovation. Moreover, his collaborative network of over 100 co-authors underscores his global impact and leadership in international scientific research.Through his pioneering studies, Dr. Hengrui Liu contributes to the development of novel therapeutic strategies, drug resistance biomarkers, and predictive computational frameworks that enhance the diagnosis, treatment, and prognosis of complex diseases such as cancer. His work exemplifies the synergy between data-driven research and molecular experimentation, reinforcing his reputation as a forward-thinking scientist shaping the future of personalized medicine and biomedical innovation.
Profiles: Scopus | ORCID | Google Scholar
Featured Publications
Liu, H., et al. (2025). CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance. Open-access Letter. 26 citations.
Liu, H., et al. (2025). In vitro antibacterial activity of neochebulinic acid from aqueous extract of Terminalia chebula Retz against Helicobacter pylori. BMC Complementary Medicine and Therapies. 1 citation.
Liu, H., et al. (2025). An in-silico pan-cancer bulk and single-cell profiling of transcription factors in protein autoubiquitination. Discover Oncology. 2 citations.
Liu, H., et al. (2025). The multidimensional role of laminin γ2 (LAMC2) on cancer progression. Review Article. 0 citations.
Liu, H., et al. (2025). Role of traditional Chinese medicine in supporting liver transplantation outcomes. World Journal of Transplantation. 4 citations.